// App-Quantinova.ai

9078 : Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ≥ 50%: Results from EMPOWER-Lung 1 study.

Researchers

Presenter

  • Mahmut Gumus

Principal Investigators

  • Cristina Ivanescu

  • Saadettin Kilickap

  • Igor Bondarenko

  • Mustafa Ozguroglu

  • Miranda Gogishvili

  • Haci M. Turk

  • Irfan Cicin

  • James Harnett

  • Vera Mastey

  • Ulrike Naumann

  • Matthew Reaney

  • Gerasimos Konidaris

  • Medha Sasane

  • Keri Brady

  • Siyu Li

  • Giuseppe Gullo

  • Petra Rietschel

  • Ahmet Sezer

Medical Centers

  • Istanbul University, Istanbul, Turkey

  • Regeneron Pharmaceuticals, Inc., Tarrytown, NY, IQVIA, Durham, NC, Department of Medical Oncology, Hacettepe University Institute of Cancer, Ankara, Turkey

  • Dnipropetrovsk Medical Academy, City Multiple-Discipline Clinical Hospital, Dnipropetrovsk, Ukraine

  • Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey

  • Nephrology, High Technology Medical Center University Clinic, Tbilisi, Georgia

  • Department of Medical Oncology, Istanbul Medipol University, Medical Faculty, Istanbul, Turkey

  • Department of Rheumatology, Trakya University Medical Faculty, Edirne, Turkey

  • Sanofi, Reading, United Kingdom

  • Sanofi, Bridgewater, NJ, Sanofi, Cambridge, MA

  • Department of Medical Oncology, Başkent University, Adana, Turkey

Locations

  • Turkey

  • Ukraine

  • Georgia

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lung Cancer

  • Non Small Cell Lung cancer

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT03088540

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved